3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
23
Gemcitabine
14
Carboplatin
10
Nivolumab
9
Cyclophosphamide
9
olaparib
8
Specimen Handling
8
Paclitaxel
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
Standard of Care
5
Irinotecan
5
Ipilimumab
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Biopsy
5
sargramostim
4
pertuzumab
4
palbociclib
4
enzalutamide
4
durvalumab
4
atezolizumab
4
aldesleukin
4
Taxes
4
Oxaliplatin
4
Fluorouracil
4
Erlotinib Hydrochloride
4
Early Intervention, Educational
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
AZD9833
×
Genitourinary
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled